CAROL GALLAGHER

Carol Gallagher is a distinguished Advisor at New Enterprise Associates (NEA), one of the world's largest and most active venture capital firms. In her role, Ms. Gallagher contributes significantly to NEA's robust healthcare investment practice, offering invaluable strategic insights and operational guidance to portfolio companies. Her expertise is particularly concentrated within the biotechnology and pharmaceutical sectors, areas where she has built an impressive career spanning several decades.

Ms. Gallagher's investment focus at NEA aligns with the firm's commitment to backing transformative companies in life sciences. She plays a crucial role in identifying promising ventures, evaluating their potential, and helping them navigate the complex landscape of drug development and commercialization. Her deep understanding of clinical development, regulatory pathways, and market dynamics makes her an indispensable resource for entrepreneurs and management teams aiming to bring innovative therapies to patients.

Before transitioning to her advisory role, Carol Gallagher served as a Venture Partner at NEA, where she was directly involved in sourcing and managing healthcare investments. Her career background is marked by a series of leadership positions in prominent biotech and pharmaceutical companies. She held executive roles at companies such as Calistoga Pharmaceuticals (acquired by Gilead Sciences), Cerimon Pharmaceuticals, Anthera Pharmaceuticals, CancerVax, and Agouron Pharmaceuticals (acquired by Pfizer). These experiences provided her with a comprehensive perspective on building and scaling successful life science businesses, from early-stage research through to commercialization.

Ms. Gallagher earned her Doctor of Pharmacy (PharmD) degree, further solidifying her scientific and clinical foundation. This unique blend of scientific expertise, operational leadership, and venture capital experience positions her as a highly respected figure in the healthcare investment community. While specific individual "notable investments" led by her in an advisory capacity are often part of a broader firm effort, her involvement has undoubtedly contributed to the success of numerous companies within NEA's healthcare portfolio, driving advancements in critical areas of medicine. Her continued dedication helps shape the future of healthcare innovation.